Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2007

View Archived Issues

New treatment for macular degeneration reported by Nippon Soda

Novel therapeutic agents for respiratory disorders disclosed in recent Argenta patents

Novel treatments for cancer covered in recent patent literature

Novel DPP II inhibitor characterized at ActivX

GW-848687X, a novel EP1 antagonist, shows potential for the treatment of inflammatory pain

Enrollment complete in CLARITY study of oral cladribine

Tanox stockholders vote in favor of Genentech merger

Lux receives orphan drug designations for ophthalmic products

DOV licenses bicifadine to XTL Biopharmaceuticals

European orphan drug designation for Prochymal

Rhucin awarded European orphan drug status

Aradigm's liposomal ciprofloxacin awarded orphan drug status for bronchiectasis

Fodosine begins pivotal study for relapsed or refractory T-cell leukemia/lymphoma

Pivotal study of prasugrel in acute coronary syndrome completes enrollment

Cicavir begins proof-of-concept study in hepatitis C

Phase II trial of VT-122 for cachexia cleared to begin

Progress in phase III study of denufosol tetrasodium for cystic fibrosis

FDA awards orphan drug status to Marqibo for ALL

U.S. orphan drug designation for defibrotide in prevention of hepatic VOD

Glufosfamide begins phase I study in Japan

MER-103 data indicate improved convenience, compliance for alendronate therapy

Silodosin shows positive effects in BPH

Phenoptin causes significant increase in phenylalanine tolerance in PKU

K-11777: New direction for schistosomiasis therapy

Sunitinib found superior to interferon alfa in metastatic renal cell cancer

Tumor necrosis therapy product launched in China for lung cancer

Provenge BLA accepted for priority review

AZD-2171 normalizes tumor vasculature in patients with glioblastoma